Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myelold leukemia:: Two cases with a different outcome

被引：27
作者：
Navarro, Jose-Torns
Feliu, Evarist
Grau, Javier
Espinet, Blanca
Colorner, Dolors
Ribera, Josep-Maria
Oriol, Albert
Granada, Isabel
Junc, Jordi
Milla, Fuensanta
机构：
[1] Hosp Germans Trias & Pujol, Inst Catala Oncol, Serv Hematol, Barcelona 08916, Spain
[2] Hosp del Mar, Lab Citogenet & Biol Mol, Barcelona, Spain
[3] Hosp Clin Barcelona, Lab Hematopatol, Barcelona, Spain
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2007年 / 82卷 / 09期
关键词：
D O I：
10.1002/ajh.20859
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chromosomal abnormalities in Ph-negative metaphases from patients with chronic myeloid leukemia (CML) treated with imatinib have been described in some cases. Trisomy 8 is the most frequent, but monosomy 7 has also been described. However, the association of these chromosomal alterations with myelodysplasia has been scarcely reported. We report the appearance of monosomy 7 in Ph-negative cells, associated with severe dysplasia, in two patients with CML treated with imatinib, with a different outcome: one with a transient evolution and the other evolving to acute myeloid leukemia.
引用
收藏
页码：849 / 851
页数：3
相关论文
共 17 条
  • [1] Clinical pharmacodynamics of antifungals
    Andes, D
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) : 635 - +
  • [2] Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
    Bumm, T
    Müller, C
    Al-Ali, HK
    Krohn, K
    Shepherd, P
    Schmidt, E
    Leiblein, S
    Franke, C
    Hennig, E
    Friedrich, T
    Krahl, R
    Niederwieser, D
    Deininger, MWN
    [J]. BLOOD, 2003, 101 (05) : 1941 - 1949
  • [3] Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones
    Chee, YL
    Vickers, MA
    Stevenson, D
    Holyoake, TL
    Culligan, J
    [J]. LEUKEMIA, 2003, 17 (03) : 634 - 635
  • [4] Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Cortes, JE
    Talpaz, M
    Giles, F
    O'Brien, S
    Rios, MB
    Shan, J
    Garcia-Manero, G
    Faclerl, S
    Thomas, DA
    Wierda, W
    Ferrajoli, A
    Jeha, S
    Kantarjian, HM
    [J]. BLOOD, 2003, 101 (10) : 3794 - 3800
  • [5] Malignancies after hematopoietic stem cell transplantation:: Many questions, some answers
    Deeg, HJ
    Socié, G
    [J]. BLOOD, 1998, 91 (06) : 1833 - 1844
  • [6] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Segal, GM
    Fanning, S
    Zimmermann, J
    Lydon, NB
    [J]. NATURE MEDICINE, 1996, 2 (05) : 561 - 566
  • [7] Mechanisms of disease - The biology of chronic myeloid leukemia
    Faderl, S
    Talpaz, M
    Estrov, Z
    O'Brien, S
    Kurzrock, R
    Kantarjian, HM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) : 164 - 172
  • [8] The emergence of Ph-, trisomy-8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate
    Feldman, E
    Najfeld, V
    Schuster, M
    Roboz, G
    Chadburn, A
    Silver, RT
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) : 702 - 707
  • [9] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 645 - 652
  • [10] Tyrosine kinases as targets for cancer therapy
    Krause, DS
    Van Etten, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) : 172 - 187
12